title: RU486 inhibits expression of lysophosphatidic acid induced glycodelin.
abstract: OBJECTIVE
  This study was undertaken to provide evidence for the mode of action of RU486 on glycodelin produced in K562 cells. To show that histiocytes may be a source of glycodelin in leiomyoma.
  
  
  METHODS
  With the use of K562, a leukemia cell line, the effect of lysophosphatidic acid (LPA), RU486, antioxidants, and ZK112,993 on glycodelin protein and gene expression was studied. Immunocytochemistry for glycodelin and HAM-56 (macrophage) was performed on leiomyoma and myometrium.
  
  
  RESULTS
  Incubation of K562 cells with LPA, progesterone, ZK112,933 and RU486 significantly induced the expression of glycodelin protein and messenger RNA. The addition of RU486 to LPA activated cells markedly reduced expression of glycodelin. Addition of ZK112,993, an antiprogestin without antioxidant properties, to LPA activated cells did not reduce glycodelin. Histiocytes in leiomyoma and myometrium co-localize with glycodelin.
  
  
  CONCLUSIONS
  RU486, partly acting as an antioxidant, markedly reduces LPA stimulated glycodelin production. Histiocytes in leiomyoma and myometrium immunostain for glycodelin and suggests a source for glycodelin in leiomyoma.
authors.affiliation: Emory University School of Medicine, Department of Gynecology and Obstetrics, Atlanta, GA, USA.
authors.forename: Sumathi
authors.initials: S
authors.lastname: Ramachandran
authors.forename: Ming Qing
authors.initials: MQ
authors.lastname: Song
authors.forename: Erin
authors.initials: E
authors.lastname: Lowe
authors.forename: Celia E
authors.initials: CE
authors.lastname: Dominguez
authors.forename: Sampath
authors.initials: S
authors.lastname: Parthasarathy
authors.forename: Ana A
authors.initials: AA
authors.lastname: Murphy
mesh_terms: D000328:Adult; D001483:Base Sequence; D001707:Biopsy, Needle; D016022:Case-Control Studies; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D006023:Glycoproteins / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D007889:Leiomyoma / Q000473:pathology; D008246:Lysophospholipids / Q000494:pharmacology*; D008875:Middle Aged; D015735:Mifepristone / Q000494:pharmacology*; D008969:Molecular Sequence Data; D011336:Probability; D012016:Reference Values; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012680:Sensitivity and Specificity; D014407:Tumor Cells, Cultured / Q000187:drug effects; D014594:Uterine Neoplasms / Q000473:pathology
chemical_list: D006023:Glycoproteins; D008246:Lysophospholipids; D015735:Mifepristone; C032881:lysophosphatidic acid